[Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions].
OBJECTIVE
Inhibition of COX-1 appears to be a key event in most non-steroidal anti-inflammatory drugs (NSAIDs)-induced adverse reactions. We evaluated celecoxib tolerance, a highly specific COX-2 inhibitor, in NSAIDs-sensitive patients.


METHODS
Intolerant patients were challenged in a single-blind study with placebo and celecoxib (increasing doses up to 400 mg).


RESULTS
We included 59 patients (41 women): 34 with urticaria with or without angiodema, 21 with bronchospasm, and 4 with urticaria and bronchospasm. Only two patients on celecoxib developed urticaria (3.4%).


CONCLUSIONS
Celecoxib is well tolerated by most NSAIDs-intolerant patients and can be a safe alternative when analgesic or antiinflammatory therapy is indicated.
Valero
Antonio
A
Servicio de Neumología y Alergia Respiratoria. Hospital Clínic. Barcelona. Spain. cpicado@medicina.ub.es
Enrique
Ernesto
E
Baltasar
Miquel
M
Cisteró
Ana
A
Martí
Enrique
E
Picado
César
C
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles; D012130:Respiratory Hypersensitivity / Q000139:chemically induced* / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib